Stocks Health care ONCY
NASDAQ · Health careOncolytics Biotech Inc (ONCY)
It posted a net loss of $28.8M. In fiscal 2025 capital spending exceeded operating cash flow by $20.1M. At June 30, 2026 it held $4.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Oncolytics Biotech Inc
- Net worth
- Oncolytics Biotech Inc has a market value (market cap) of $48.7M at the latest share price, and shareholders' equity of -$6.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2017 revenue was $6.2M.
- Cash flow
- In fiscal 2025 operations used $20.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Oncolytics Biotech Inc does
Oncolytics Biotech Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ONCY.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$28.8M | -$0.30 | -$20.1M |
| 2025 | n/a | -$22.8M | -$0.30 | -$20.1M |
| 2017 | $6.2M | n/a | n/a | n/a |
| 2017 | $0 | n/a | n/a | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Oncolytics Biotech Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026Additional proxy material DEFA14A
- October 6, 2026Proxy statement DEF 14A
- September 29, 2026Other event 8-K
- September 28, 2026Other event 8-K
- September 10, 2026Other event 8-K
- August 18, 2026Other event 8-K
- August 12, 2026
- July 24, 2026
- July 20, 2026Other event 8-K
- July 13, 2026Other event 8-K
Insider trades
What the people running Oncolytics Biotech Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| March 12, 2026 | Kelly JaredChief Executive Officer, Director | Bought | 5,050 | $4.8K |
| March 11, 2026 | Parsons James T.Director | Bought | 10,000 | $10.3K |
| February 12, 2026 | Andrews Patricia SDirector | Bought | 35,400 | $30.3K |
| February 12, 2026 | Brown Deborah MargaretDirector | Bought | 25,000 | $21.2K |
| February 12, 2026 | Hagerman AllisonVP, Product Development | Bought | 10,000 | $8.3K |
| February 12, 2026 | Heineman Thomas CharlesChief Medical Officer | Bought | 12,132 | $10K |
| February 12, 2026 | Kelly JaredChief Executive Officer, Director | Bought | 29,500 | $24.8K |
| February 12, 2026 | Look KirkChief Financial Officer | Bought | 12,000 | $10.1K |
Who owns ONCY
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Anson Funds Management LP13G, passive with 5 related filers | 7% | November 14, 2025 |
Largest institutional holders
Insiders
10 insiders reported holding 2,143,775 shares in total, about $818.5K at the last price.
| Holder | Shares |
|---|---|
| Seizinger Bernd R.Director | 566,991 |
| Pisano WayneDirector | 492,414 |
| Look KirkChief Financial Officer | 287,515 |
| Heineman Thomas CharlesChief Medical Officer | 282,818 |
| Hagerman AllisonVP, Product Development | 115,059 |
| Kelly JaredChief Executive Officer, Director | 114,050 |
| Brown Deborah MargaretDirector | 109,851 |
| Andrews Patricia SDirector | 78,128 |
| Aromando AndrewChief Business Officer | 55,100 |
| Parsons James T.Director | 41,849 |
Questions about ONCY
What does Oncolytics Biotech Inc do?
Oncolytics Biotech Inc is a company in the Health care sector, listed on NASDAQ as ONCY. Its shares trade on NASDAQ under the ticker ONCY.
What is Oncolytics Biotech Inc's net worth?
Oncolytics Biotech Inc has a market value (market cap) of $48.7M at the latest share price, and shareholders' equity of -$6.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Oncolytics Biotech Inc profitable?
No. In fiscal 2025 it reported a net loss of $28.8M.
When did Oncolytics Biotech Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the additional proxy material from October 6, 2026.
Similar companies
Compare ONCY with
Follow ONCY
Get an email when Oncolytics Biotech Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Oncolytics Biotech Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.